Latest news with #NEXTMedicalWritingAutomation
Business Standard
14-07-2025
- Business
- Business Standard
Stock Alert: Dmart, Ajmera Realty, Rites, RVNL, Indegene, Gland Pharma
Securities in F&O Ban: Glenmark Pharma, Hindustan Copper and RBL Bank shares are banned from F&O trading on 14 July 2025. Upcoming Results: HCLTech, Ola Electric, Rallis India, Tata Technologies, Tejas Networks, Kesoram Industries will announce their quarterly results later today. Stocks To watch: Avenue Supermarts (Dmart)s consolidated net profit fell 0.11% to Rs 772.97 crore despite a 16.28% jump in revenue from operations to Rs 16,359.70 crore in Q1 FY26 over Q1 FY25. Ajmera Realty & Infra reported 65% decline in sales value to Rs 108 crore in Q1 FY26 compared with Rs 306 crore in Q1 FY25. Collection jumped 42% YoY to Rs 234 crore in Q1 FY26, underscoring strong cash flow realization from existing projects. Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. RITES said that it has received an order for undertaking the construction and renovation of Government First Grade College at various locations in Karnataka under the PM USHA Scheme. The project cost, including RITES fees, is Rs 46.82 crore. The project has to be executed within a period of 36 months. Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. Rail Vikas Nigam (RVNL) has been awarded a letter of acceptance (LoA) by the South Central Railway for a significant project valued at Rs 213.22 crore. The contract encompasses the design, supply, erection, testing, and commissioning of an overhead equipment (OHE) upgradation project. NCC announced that it has received a Letter of Acceptance (LoA) worth Rs 2,269 crore from the Mumbai Metropolitan Region Development Authority (MMRDA) for work on the Mumbai Metro Line 6 project. RailTel Corporation of India has received a work order from Indian Overseas Bank, valued at Rs 10.27 crore. The project is scheduled to be executed by 7 August 2025. IRB Infrastructure Developers, along with its InvIT associate IRB Infrastructure Trust, reported combined toll revenue of Rs 1,680 crore for the AprilJune quarter of FY26, marking an 8% year-on-year increase from Rs 1,556 crore in Q1 FY25.
Business Standard
12-07-2025
- Business
- Business Standard
Indegene launches NEXT Medical Writing Automation
Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegenes decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automationits about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting. Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecyclemore effectively, efficiently, and in a modern, technology-driven manner. The companys consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.
